Description

Drug Classification:

Sitagliptin and Metformin belong to different classes of antidiabetic agents:

• Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which enhances insulin secretion and decreases glucagon production.
• Metformin is a biguanide that primarily reduces hepatic glucose production and enhances peripheral glucose uptake.

Formulations:

• Sitagliptin + Metformin Tablets:
  • Strength: Available in two formulations:
    • Sitagliptin 50mg / Metformin 500mg Tablets (14’s)
    • Sitagliptin 50mg / Metformin 1000mg Tablets (14’s)
  • Product Form: Oral tablets for easy administration.
  • Packing Specifications: Packaged in blister packs containing 14 tablets each, ensuring convenience and freshness.

Indications:

Sitagliptin + Metformin Tablets are indicated for the treatment of type 2 diabetes mellitus in adults. This combination medication helps improve glycemic control by addressing multiple pathophysiological aspects of diabetes, including insulin secretion, insulin sensitivity, and hepatic glucose production.

Usage:

• Sitagliptin + Metformin Tablets should be taken orally with meals to reduce the risk of gastrointestinal side effects associated with Metformin.
• It is essential to adhere to the prescribed dosage and regimen recommended by your healthcare provider.
• Regular monitoring of blood glucose levels is necessary to assess treatment efficacy and adjust dosage as needed.

Dosage:

• The dosage of Sitagliptin + Metformin Tablets may vary depending on the patient’s individual response to treatment and glycemic control goals.
• The usual starting dose is one tablet twice daily, with gradual titration based on blood glucose levels and tolerance.
• Dosage adjustments may be necessary in patients with renal impairment or other comorbidities.

Pharmacokinetics:

• Sitagliptin is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 1-4 hours.
• Metformin is also rapidly absorbed, with peak plasma concentrations reached within 2-3 hours.
• Both Sitagliptin and Metformin undergo renal elimination, with Metformin predominantly excreted unchanged in the urine.

Pharmacodynamics:

• Sitagliptin works by inhibiting the enzyme DPP-4, which inactivates incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Sitagliptin prolongs the action of these incretins, leading to increased insulin secretion and decreased glucagon release, resulting in lower blood glucose levels.
• Metformin acts primarily by decreasing hepatic glucose production and enhancing peripheral glucose uptake, thereby lowering blood glucose levels.

Side Effects:

• Common side effects of Sitagliptin + Metformin Tablets may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort.
• Rare but serious side effects may include lactic acidosis, particularly in patients with renal impairment or other predisposing factors.
• Contact your healthcare provider immediately if you experience severe or persistent side effects while taking Sitagliptin + Metformin Tablets.

Experience the efficacy and convenience of Sitagliptin + Metformin Tablets from AIT Pharmaceuticals Division. Trust in our commitment to providing quality medications to improve the lives of patients with type 2 diabetes mellitus. For more information, please visit our website or consult your healthcare provider.